Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $17.00 by Analysts at Citigroup

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its target price dropped by stock analysts at Citigroup from $35.00 to $17.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective points to a potential upside of 216.10% from the stock’s current price.

EYPT has been the topic of several other reports. HC Wainwright reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Cantor Fitzgerald lowered shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday. Jefferies Financial Group lowered their price target on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a report on Monday. Royal Bank Of Canada restated a “sector perform” rating and set a $5.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Finally, Stifel Nicolaus started coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.11.

Eyepoint Pharmaceuticals Stock Up 10.4%

Shares of EYPT stock traded up $0.51 on Tuesday, reaching $5.38. The stock had a trading volume of 9,446,036 shares, compared to its average volume of 1,677,884. Eyepoint Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $19.11. The firm has a market capitalization of $463.64 million, a price-to-earnings ratio of -1.43 and a beta of 1.76. The firm’s 50-day moving average is $13.10 and its two-hundred day moving average is $13.62.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. On average, sell-side analysts forecast that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

Institutional Trading of Eyepoint Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. KBC Group NV bought a new stake in shares of Eyepoint Pharmaceuticals in the first quarter valued at approximately $29,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after acquiring an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Eyepoint Pharmaceuticals during the third quarter valued at approximately $76,000. Tower Research Capital LLC TRC raised its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: DURAVYU was reported as non-inferior to aflibercept in an ad hoc analysis that excluded an asymmetric group of nine patients whose vision loss was considered unrelated to wet AMD. The company also highlighted a 42% reduction in treatment burden, favorable safety with redosing, strong anatomic control, and other supportive secondary endpoints. EyePoint LUGANO trial results
• Positive Sentiment: Jefferies maintained a “buy” rating while lowering its price target to $8, implying substantial upside from recent trading levels. Chardan also previously maintained a bullish rating, although its latest view has changed.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the clinical-trial results were released, reflecting the market significance of the announcement.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating, while JPMorgan reaffirmed its neutral view. Chardan Capital and RBC also reaffirmed neutral or sector-perform ratings, each assigning a $5 price target.
• Negative Sentiment: The full LUGANO dataset did not achieve the trial’s primary endpoint, a major setback for DURAVYU’s regulatory and commercial prospects. The company may need to explain the impact of the vision-loss cohort and how the remaining Phase 3 program will proceed. Reuters EyePoint trial report
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral,” while multiple analysts have reduced or reaffirmed cautious price targets. Investor discussion has also shifted toward competing ophthalmology companies as potentially stronger opportunities.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.